The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Risankizumab Effective Against Refractory Psoriatic Arthritis

Risankizumab Effective Against Refractory Psoriatic Arthritis

January 22, 2022 • By Matthew Phelan

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial.

You Might Also Like
  • Risankizumab May Improve Symptoms of PsA
  • Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis

“Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse disease manifestations in patients who have not responded adequately to standard treatment,” Dr. Lars Erik Kristensen of the University of Copenhagen and colleagues write in BMJ Annals of the Rheumatic Diseases.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Current first-line treatments for PsA include non-steroidal anti-inflammatory drugs, local corticosteroid injections for musculoskeletal symptoms and topical therapies for psoriasis. For patients with an inadequate response or poor prognosis, conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), antitumor necrosis factor therapy and other biologics are recommended.

Risankizumab, a humanized IgG1 monoclonal antibody that specifically targets IL-23’s p19 subunit, has been approved by the U.S. Food and Drug Administration as a treatment for moderate to severe plaque psoriasis, but not PsA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“I really welcome a new mode of action, which we will have to learn how to optimally use in PsA patients,” Dr. Kristensen tells Reuters Health by email. “We have patients with PsA who do not respond or tolerate the drugs we had so far for treating this.”

In the double-blind KEEPsAKE 1, Dr. Kristensen and his colleagues randomly assigned 964 patients with active PsA to receive 150 mg of risankizumab or placebo at zero, four and 16 weeks. The primary endpoint was the proportion of patients whose symptoms improved by 20% or more based on the ACR20 criteria at week 24.

All patients were adults whose PsA symptoms had lasted at least six months, in accordance with the Classification Criteria for Psoriatic Arthritis. They had five or more tender joints; five or more swollen joints; one or more cases of erosion based on a centrally read radiograph (hands, feet or both) or high-sensitivity C-reactive protein (at least 3.0 mg/L); and active plaque psoriasis, defined as at least one psoriatic plaque of 2 cm or more in diameter or nail psoriasis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The participants had previously had an inadequate response, intolerance, or a likely risk of harm from one or more csDMARDs. Continuation of concomitant therapy with two or fewer csDMARDs was allowed, but patients with prior exposure to biologics were excluded. The percentage of patients undergoing concomitant csDMARD treatment was similar between the risankizumab and placebo groups (76.0% vs. 76.7%, respectively).

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: PsA, PsA Resource Center, Psoriatic Arthritis, refractory PsA, risankizumab

You Might Also Like:
  • Risankizumab May Improve Symptoms of PsA
  • Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis
  • Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)